An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.

Abstract

INTRODUCTION:

Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults.

AIMS:

To update the evidence and provide an overview of the available data on icatibant.

EVIDENCE REVIEW:

Peer reviewed articles published and listed in Medline Search and published updated guidelines for the treatment of acute attacks in hereditary angioedema type I and II in adults were reviewed. The validity and quality of evidence were evaluated.

PLACE IN THERAPY:

Clinical evidence for the treatment of acute hereditary angioedema attacks with icatibant is strong. Approximately 10% of the patients require a second dose. No serious adverse reactions have been reported. The only significant side effects consistently registered by 90% of patients are transient local pain, swelling, and erythema at the local injection site.

CONCLUSION:

Subcutaneously administered 30 mg icatibant has been shown to be a safe and efficacious treatment in clinical trials. It is the only specific treatment authorized for self-administration by the subcutaneous route offering increased patient independence.

• Authors: Bernard Floccard, Etienne Hautin, Laurence Bouillet, Brigitte Coppere, Bernard Allaouchiche
• Journal: Core evidence (Core Evid) Vol. 7 Pg. 105-14 ( 2012) ISSN: 1555-175X [Electronic] New Zealand
• PMID: 23055948 (Publication Type: Journal Article)